<SEC-DOCUMENT>0001437749-23-008873.txt : 20230331
<SEC-HEADER>0001437749-23-008873.hdr.sgml : 20230331
<ACCEPTANCE-DATETIME>20230331171316
ACCESSION NUMBER:		0001437749-23-008873
CONFORMED SUBMISSION TYPE:	S-8
PUBLIC DOCUMENT COUNT:		5
REFERENCES 429:			333-218469
REFERENCES 429:			333-222625
REFERENCES 429:			333-236328
REFERENCES 429:			333-252155
REFERENCES 429:			333-264953
FILED AS OF DATE:		20230331
DATE AS OF CHANGE:		20230331
EFFECTIVENESS DATE:		20230331

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NovaBay Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001389545
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				680454536
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-8
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-271053
		FILM NUMBER:		23789114

	BUSINESS ADDRESS:	
		STREET 1:		2000 POWELL STREET, SUITE 1150
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608
		BUSINESS PHONE:		(510) 899-8800

	MAIL ADDRESS:	
		STREET 1:		2000 POWELL STREET, SUITE 1150
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-8
<SEQUENCE>1
<FILENAME>nby20230328_s8.htm
<DESCRIPTION>FORM S-8
<TEXT>
<html><head>
	<title>nby20230328_s8.htm</title>

	<!-- Generated by ThunderDome Portal - 3/31/2023 8:30:35 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 75%;">As filed with the Securities and Exchange Commission on March 31, 2023.&nbsp;</td>
			<td style="width: 25%;">Registration No. 333-</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>UNITED STATES</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Washington, D.C. 20549</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>FORM S-8</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">REGISTRATION STATEMENT</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">UNDER</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">THE SECURITIES ACT OF 1933</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>NovaBay Pharmaceuticals, Inc.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Exact name of registrant as specified in its charter)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 100%;">

		<tr>
			<td style="vertical-align:top;width:34.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Delaware </b></p>
			</td>
			<td style="vertical-align:top;width:34.1%;">&nbsp;</td>
			<td style="vertical-align:top;width:35.3%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>68-0454536</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:34.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(State or other jurisdiction of incorporation or organization)</p>
			</td>
			<td style="vertical-align:top;width:34.1%;">&nbsp;</td>
			<td style="vertical-align:top;width:35.3%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">(I.R.S. Employer Identification No.)</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>2000 Powell Street, Suite 1150, Emeryville, CA 94608</b><br>
<b>(510) 899-8800</b><br>
(Address, including zip code, of Principal Executive Offices)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>2017 Omnibus Incentive Plan</b><br>
(Full title of the plan)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Justin M. Hall, Esq.</b><br>
<b>Chief Executive Officer and General Counsel</b><br>
<b>2000 Powell Street, Suite 1150</b><br>
<b>Emeryville, CA 94608</b><br>
<b>(510) 899-8800</b><br>
(Name, address, and telephone number, including area code, of agent for service)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Copies to:<br>
<b>Abby E. Brown, Esq.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Squire Patton Boggs (US) LLP</b><br>
<b>2550 M Street, Northwest</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Washington, DC 20037</b><br>
<b>(202) 457-6000</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 50%; padding-left: 36pt;">Large accelerated filer &#9744;</td>
			<td style="width: 50%;">Accelerated filer &#9744;</td>
		</tr>
		<tr>
			<td style="padding-left: 36pt;">Non-accelerated filer &#9746;</td>
			<td>Smaller reporting company &#9746;</td>
		</tr>
		<tr>
			<td>&nbsp;</td>
			<td>Emerging growth company &#9744;</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. &#9744;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>EXPLANATORY NOTE</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">This Registration Statement on Form S-8 registers a total of 81,417 shares of common stock, par value $0.01 per share (the &#8220;Common Stock&#8221;), of NovaBay Pharmaceuticals, Inc., a Delaware corporation (the &#8220;Company&#8221;), for issuance under the NovaBay Pharmaceuticals, Inc. 2017 Omnibus Incentive Plan (the &#8220;Plan&#8221;). The shares of Common Stock being registered by this Registration Statement give effect to the Company&#8217;s 1-for-35 reverse stock split that was effective on November 15, 2022 (the &#8220;Reverse Stock Split&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The number of shares of Common Stock available for issuance under the stockholder-approved Plan is subject to an automatic annual increase on the first day of each of the Company&#8217;s fiscal years beginning on January 1, 2018 and ending on January 1, 2027 by an amount equal to (i)&nbsp;four percent (4%)&nbsp;of the number of shares of Common Stock outstanding on the last day of the immediately preceding fiscal year or (ii)&nbsp;such lesser number of shares of Common Stock as determined by the Board of Directors (the &#8220;Board&#8221;).&nbsp; For 2023, the Board authorized an increase of 81,417 shares of the Common Stock under the Plan, consisting of the full four percent (4%) increase allowed pursuant to the Plan&#8217;s evergreen provision. These shares are in addition to the 66,243 shares of Common Stock registered on the Company&#8217;s Form S-8 filed on June 2, 2017 (File No. 333-218469), the 17,583 shares of Common Stock registered on the Company&#8217;s Form S-8 filed on January 19, 2018 (File No. 333-222625) pursuant to the annual increase in 2018 according to the Plan&#8217;s evergreen provision, the 51,460 shares of Common Stock registered on the Company&#8217;s Form S-8 filed on February 7, 2020 (File No. 333-236328) pursuant to the annual increases in 2019 and 2020 according to the Plan&#8217;s evergreen provision (with 19,531 shares of Common Stock from the 2019 annual increase and 31,929 shares of Common Stock from the 2020 annual increase), the 47,752 shares of Common Stock registered on the Company&#8217;s Form S-8 filed on January 15, 2021 (File No. 333-252155) pursuant to the annual increase in 2021 according to the Plan&#8217;s evergreen provision, and the 54,590 shares of Common Stock registered on the Company&#8217;s Form S-8 filed on May 13, 2022 (File No. 333-264953) pursuant to the annual increase in 2022 according to the Plan&#8217;s evergreen provision. Since the Plan provides that the annual increase in the aggregate number of shares that may be issued pursuant to the Plan&#8217;s evergreen provision begins for fiscal years commencing January 1, 2018, this Registration Statement accounts for the sixth share increase under the evergreen provision. The number of shares of Common Stock registered under each prior Registration Statement listed above has been adjusted to account for the Reverse Stock Split.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The contents of the prior Registration Statements on Form S-8 filed with the Securities and Exchange Commission (the &#8220;Commission&#8221;) on June 2, 2017, January 19, 2018, February 7, 2020, January 15, 2021 and May 13, 2022 (File Nos. 333-218469, 333-222625, 333-236328, 333-252155, and 333-264953<u>,</u> respectively), are incorporated herein by reference and made part of this Registration Statement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">This Registration Statement relates to securities of the same class as those to which the prior Registration Statements listed directly above relate, and is submitted in accordance with General Instruction E to Form S-8 regarding the Registration of Additional Securities. Pursuant to General Instruction E of Form S-8, the contents of the prior Registration Statements are incorporated herein by reference and made part of this Registration Statement, except as amended hereby.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>PART</b><b> II</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>INFORMATION REQUIRED IN THE REGISTRATION STATEMENT</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 3.</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Incorporation of Documents by Reference.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">The following documents filed by the Company with the Commission are incorporated by reference into this Registration Statement:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">1.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the Commission on <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0001389545/000143774923008843/nby20221231_10k.htm" style="-sec-extract:exhibit;">March 31, 2023.</a></p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 18pt; text-align: justify;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">2.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Company&#8217;s Current Report on Form 8-K filed with the Commission on <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0001389545/000143774923001446/nby20230120_8k.htm" style="-sec-extract:exhibit;">January 20, 2023</a>.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The description of the Company&#8217;s Common Stock which is contained in the Company&#8217;s registration statement on Form 8-A, as filed with the Commission on <a href="http://www.sec.gov/Archives/edgar/data/1389545/000119312507191730/d8a12b.htm" style="-sec-extract:exhibit;">August 29, 2007</a><u>,</u>&nbsp;as updated by <a href="http://www.sec.gov/Archives/edgar/data/1389545/000143774923008843/ex_485491.htm" style="-sec-extract:exhibit;">Exhibit 4.1</a>&nbsp;to our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, together with any amendment or report filed for the purpose of updating such description.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">All reports and other documents subsequently filed by the Company pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any such information so modified or superseded shall not be deemed, except as so modified or superseded, to constitute part of this Registration Statement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Notwithstanding the foregoing, we are not incorporating by reference information furnished under Items 2.02 and 7.01 of any Current Report on Form 8-K, including the related exhibits, nor any other document or information deemed to have been furnished and not filed in accordance with Commission rules.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 4.</b>&nbsp; <b>Description of Securities. </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Not applicable.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 5.</b>&nbsp; <b>Interests of Named Experts and Counsel.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The validity of the issuance of the shares of Common Stock registered under this Registration Statement has been passed upon for the Company by Squire Patton Boggs (US) LLP.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 6.</b>&nbsp; <b>Indemnification of Directors and Officers.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The Company&#8217;s amended and restated certificate of incorporation, as amended, provides that the liability of the directors for monetary damages shall be eliminated to the fullest extent under applicable law. If the Delaware General Corporation Law is amended to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director of the Company shall be eliminated to the fullest extent permitted by the Delaware General Corporation Law, as so amended. Under the Delaware General Corporation Law, no director will be personally liable to the Company or the Company&#8217;s stockholders for monetary damages for breach of fiduciary duty as a director, except for liability:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">for any breach of the duty of loyalty to the Company or the Company&#8217;s stockholders;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">for acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">for unlawful payment of dividends or unlawful stock repurchases or redemptions under Section 174 of the Delaware General Corporation Law; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">for any transaction from which the director derived an improper personal benefit.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The Company&#8217;s amended and restated bylaws provide that:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the Company is required to indemnify the Company&#8217;s directors and executive officers to the fullest extent not prohibited by Delaware law, subject to limited exceptions;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the Company may indemnify the Company&#8217;s other employees and agents as set forth in the Delaware General Corporation Law;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the Company is required to advance expenses to the Company&#8217;s directors and executive officers as incurred in connection with legal proceedings against them for which they may be indemnified, against an undertaking by the indemnified party to repay such advances if it is ultimately determined that the indemnified party is not entitled to indemnification; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the rights conferred in the amended and restated bylaws are not exclusive.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The information provided above is a summary of relevant provisions of our amended and restated certificate of incorporation, as amended, our amended and restated bylaws and certain provisions of the Delaware General Corporation Law. We urge you to read the full text of these documents, forms of which have been filed with the Commission, as well as the referenced provisions of the Delaware General Corporation Law because they are the legal documents and provisions that will govern matters of indemnification with respect to our directors and officers.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The Company has entered into indemnification agreements with each of the Company&#8217;s directors and executive officers that require the Company to indemnify these persons against all direct and indirect costs of any type or nature whatsoever, including attorney&#8217;s fees, witness fees, and other out-of-pocket costs of whatever nature, incurred by the director or officer in any action or proceeding, whether actual, pending or threatened, subject to certain limitations, to which any of these people may be made a party by reason of the fact that he or she is or was a director or an executive officer of the Company or is or was serving or at any time serves at the request of the Company as a director, officer, employee or other agent of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The Company has purchased insurance on behalf of any person who is or was a director or officer of the Company against any loss arising from any claim asserted against him or her and incurred by him or her in any such capacity, subject to certain exclusions.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 7.</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Exemption from Registration Claimed.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Not applicable.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 8.</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Exhibits.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 100%;">

		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:13.7%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"><b>Exhibit No.</b></p>
			</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:83.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Description of Document</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">3.1</p>
			</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1389545/000143774918005177/ex_107885.htm" style="-sec-extract:exhibit;"><u>Amended and Restated Certificate of Incorporation of NovaBay Pharmaceuticals, Inc., a Delaware corporation (incorporated by reference to Exhibit 3.1 of the Company</u><u>&#8217;</u><u>s Current Report on Form 8-K, as filed with the Commission on March 21, 2018 (File No. 001-33678))</u></a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">3.2</p>
			</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1389545/000143774918011215/ex_115851.htm" style="-sec-extract:exhibit;"><u>Certificate of Amendment to Amended and Restated Certificate of Incorporation of NovaBay Pharmaceuticals, Inc., a Delaware corporation (incorporated by reference to Exhibit 3.1 of the Company</u><u>&#8217;</u><u>s Current Report on Form 8-K, as filed with the Commission on June 4, 2018 (File No. 001-33678))</u></a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">3.3</p>
			</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1389545/000143774920011939/ex_188182.htm" style="-sec-extract:exhibit;">Certificate of Amendment to Amended and Restated Certificate of Incorporation of NovaBay Pharmaceuticals, Inc., a Delaware corporation (incorporated by reference to Exhibit 3.1 of the Company&#8217;s Current Report on Form 8-K, as filed with the Commission on May 28, 2020 (File No. 001-33678))<u>&nbsp;</u></a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">3.4</p>
			</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/0001389545/000143774921013167/ex_252546.htm" style="-sec-extract:exhibit;">Certificate of Amendment to Amended and Restated Certificate of Incorporation of NovaBay Pharmaceuticals, Inc., a Delaware corporation (incorporated by reference to Exhibit 3.1 of the Company&#8217;s Current Report on Form 8-K, as filed with the Commission on May 24, 2021 (File No. 001-33678))<u>&nbsp;</u></a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">3.5</p>
			</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1389545/000143774922002101/ex_330469.htm" style="-sec-extract:exhibit;">Certificate of Amendment to Amended and Restated Certificate of Incorporation of NovaBay Pharmaceuticals, Inc., a Delaware corporation (incorporated by reference to Exhibit 3.1 of the Company&#8217;s Current Report on Form 8-K, as filed with the Commission on February 1, 2022 (File No. 001-33678))</a></p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 100%;">

		<tr>
			<td style="vertical-align:top;width:13.7%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">3.6</p>
			</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/0001389545/000143774921024705/ex_300010.htm" style="-sec-extract:exhibit;">Certificate of Designation for the Series B Preferred Stock (incorporated by reference to Exhibit 3.1 of the Company&#8217;s Current Report on Form 8-K, as filed with the Commission on November 1, 2021 (File No. 001-33678))</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">3.7</p>
			</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1389545/000143774922027767/ex_448350.htm" style="-sec-extract:exhibit;">Certificate of Amendment to Amended and Restated Certificate of Incorporation of NovaBay Pharmaceuticals, Inc., a Delaware corporation (incorporated by reference to Exhibit 3.1 of the Company&#8217;s Current Report on Form 8-K, as filed with the Commission on November 18, 2022 (File No. 001-33678))</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">3.8</p>
			</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1389545/000143774922027767/ex_448351.htm" style="-sec-extract:exhibit;">Certificate of Designation for the Series C Preferred Stock (incorporated by reference to Exhibit 3.2 of the Company&#8217;s Current Report on Form 8-K, as filed with the Commission on November 18, 2022 (File No. 001-33678))</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">3.9</p>
			</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1389545/000143774922007543/ex_351428.htm" style="-sec-extract:exhibit;">Amended and Restated Bylaws of NovaBay Pharmaceuticals, Inc., a Delaware corporation (incorporated by reference to Exhibit 3.7 to the Company&#8217;s Annual Report on Form 10-K, as filed with the Commission on March 29, 2022 (File No. 001-33678))</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">4.1</p>
			</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Reference is made to Exhibits&nbsp;<a href="http://www.sec.gov/Archives/edgar/data/1389545/000143774918005177/ex_107885.htm" style="-sec-extract:exhibit;">3.1</a>,&nbsp;<a href="http://www.sec.gov/Archives/edgar/data/1389545/000143774918011215/ex_115851.htm" style="-sec-extract:exhibit;">3.2</a>, <a href="http://www.sec.gov/Archives/edgar/data/1389545/000143774920011939/ex_188182.htm" style="-sec-extract:exhibit;">3.3</a>, <a href="http://www.sec.gov/Archives/edgar/data/1389545/000143774921013167/ex_252546.htm" style="-sec-extract:exhibit;">3.4</a>, <a href="http://www.sec.gov/Archives/edgar/data/1389545/000143774922002101/ex_330469.htm" style="-sec-extract:exhibit;">3.5</a>, <a href="http://www.sec.gov/Archives/edgar/data/1389545/000143774922027767/ex_448350.htm" style="-sec-extract:exhibit;">3.6</a>, <a href="http://www.sec.gov/Archives/edgar/data/0001389545/000143774921024705/ex_300010.htm" style="-sec-extract:exhibit;">3.7</a> and <a href="http://www.sec.gov/Archives/edgar/data/1389545/000143774922027767/ex_448351.htm" style="-sec-extract:exhibit;">3.8</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">4.2</p>
			</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1389545/000119312507178794/dex41.htm" style="-sec-extract:exhibit;"><u>Specimen Common Stock Certificate (incorporated by reference to the exhibit of the same description from the Company</u><u>&#8217;</u><u>s</u><u>&nbsp;</u><u>amendment to the registration statement on</u><u>&nbsp;</u><u>Form S-1 filed with the SEC on August 10, 2007 (SEC File No. 333-140714))</u></a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">5.1*</p>
			</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="ex_494384.htm" style="-sec-extract:exhibit;">Opinion of Squire Patton Boggs (US) LLP</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">23.1*</p>
			</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="ex_495178.htm" style="-sec-extract:exhibit;">Consent of WithumSmith+Brown, PC</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">23.2*</p>
			</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="ex_494384.htm" style="-sec-extract:exhibit;">Consent of Squire Patton Boggs (US) LLP (included in Exhibit 5.1)</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">24.1*</p>
			</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="#sigs" style="-sec-extract:exhibit;">Power of Attorney to file future amendments (set forth on the signature page of this Registration Statement)</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">99.1</p>
			</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1389545/000143774917010557/ex99-1.htm" style="-sec-extract:exhibit;">NovaBay Pharmaceuticals, Inc. 2017 Omnibus Incentive Plan (incorporated by reference to Exhibit 99.1 to the Company&#8217;s Registration Statement on Form S-8 (File No. 333-218469), as filed with the Commission on June 2, 2017)</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">99.2</p>
			</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1389545/000143774917010557/ex99-2.htm" style="-sec-extract:exhibit;">Forms of agreements for use under the NovaBay Pharmaceuticals, Inc. 2017 Omnibus Incentive Plan (incorporated by reference to Exhibit 99.2 to the Company&#8217;s Registration Statement on Form S-8 (File No. 333-218469), as filed with the Commission on June 2, 2017)</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 13.7%; padding: 0pt 0pt 0pt 9pt;">&nbsp;</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">99.3</p>
			</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/0001389545/000143774921011142/ex_245260.htm" style="-sec-extract:exhibit;">Performance Restricted Stock Unit Award Agreement with Mr. Justin Hall (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q (File No. 001-33678), as filed with the Commission on May 6, 2021)</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">99.4</p>
			</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/0001389545/000143774921026234/ex_306149.htm" style="-sec-extract:exhibit;">Performance Restricted Stock Unit Award Agreement with Dr. Audrey Kunin (incorporated by reference to Exhibit 10.4 to the Company&#8217;s Current Report on Form 8-K (File No. 001-33678), as filed with the Commission on November 12, 2021)&nbsp; &nbsp;&nbsp;</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">107*</p>
			</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_494385.htm" style="-sec-extract:exhibit;">Filing Fee Table</a></p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; vertical-align: top;">*&nbsp; Exhibits marked with an asterisk (*) are filed herewith.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Item 9.</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Undertakings. </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Incorporated by reference to Item 9 in the Company&#8217;s Registration Statement on Form S-8, filed with the Commission on June 2, 2017.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="sigs" name="sigs" title="sigs"></a>SIGNATURES</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Pursuant to the requirements of the Securities Act of 1933, as amended, the Company certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Emeryville, State of California on March 31, 2023.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="text-indent: 0; width: 100%;font-family: 'Times New Roman', Times, serif; font-size: 10pt">

		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td colspan="1" valign="top" width="38%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b>NOVABAY PHARMACEUTICALS, INC.</b></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td align="left" nowrap="nowrap" valign="bottom" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td align="left" style="text-align: left;" valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td align="left" nowrap="nowrap" style="BORDER-BOTTOM: #000000 1px solid" valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">/s/&nbsp;Justin M. Hall</p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Justin M. Hall</p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Chief Executive Officer and General Counsel</p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">KNOW ALL PERSONS BY THESE PRESENTS that each of the undersigned officers and directors does hereby constitute and appoint Justin M. Hall or his substitute or substitutes, as his or her true and lawful attorney-in-fact and agent, with full power and authority to do any and all acts and things and to execute and file or cause to be filed any and all instruments, documents or exhibits which said attorney and agent determines may be necessary or advisable or required to enable said corporation to comply with the Securities Act of 1933, as amended, and any rules or regulations or requirements of the Securities and Exchange Commission in connection with this Registration Statement. Without limiting the generality of the foregoing power and authority, the powers granted include the power and authority to sign the names of the undersigned officers and directors in the capacities indicated below to this Registration Statement, to any and all amendments, both pre-effective and post-effective, and supplements to this Registration Statement and to any and all instruments, documents or exhibits filed as part of, or in conjunction with, this Registration Statement or amendments or supplements thereof, with the powers of substitution and revocation, and each of the undersigned hereby ratifies and confirms all that said attorney and agent, or his substitute or substitutes, shall lawfully do or cause to be done by virtue hereof. In witness whereof, each of the undersigned has executed this Power of Attorney as of the dates indicated below.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated. This document may be executed by the signatories hereto on any number of counterparts, all of which shall constitute one and the same instrument.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 100%;">

		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Signature</b></p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Title</b></p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Date</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 32%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 32%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 32%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Justin M. Hall</p>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Chief Executive Officer, General Counsel and Director</p>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;March 31, 2023</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Justin M. Hall</p>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>(principal executive officer)</i></p>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 32%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 32%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 32%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 32%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Tommy Law</p>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Interim Chief Financial Officer</p>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 31, 2023</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Tommy Law</p>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>(principal financial and accounting officer)</i></p>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 32%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 32%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 32%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 32%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Paul E. Freiman</p>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Chairman</p>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 31, 2023</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Paul E. Freiman, Ph.D</p>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 32%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 32%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 32%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 32%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 32%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Julie Garlikov</p>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Director</p>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 31, 2023</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Julie Garlikov</p>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 32%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 32%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 32%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 32%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 32%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Audrey Kunin</p>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Director</p>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 31, 2023</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Audrey Kunin, M.D.</p>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 32%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 32%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 32%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 32%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 32%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Swan Sit</p>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Director</p>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 31, 2023</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Swan Sit</p>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 32%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 32%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 32%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 32%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 32%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Mijia (Bob) Wu</p>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Director</p>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 31, 2023</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Mijia (Bob) Wu</p>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 32%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 32%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 32%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 32%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Yenyou (Jeff) Zheng</p>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Director</p>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 31, 2023</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Yenyou (Jeff) Zheng, Ph.D</p>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 32%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 32%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 32%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 32%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 32%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Yongxiang (Sean) Zheng</p>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Director</p>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 31, 2023</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Yongxiang (Sean) Zheng</p>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 32%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 32%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>ex_494384.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<html><head>
	<title>ex_494384.htm</title>

	<!-- Generated by ThunderDome Portal - 3/31/2023 6:51:45 AM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;">
<p style="margin: 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 5.1</b></font></p>

<p style="margin: 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 50%; vertical-align: top;">
			<div><img alt="spblogo.jpg" src="spblogo.jpg"></div>
			</td>
			<td style="width: 50%;">Squire Patton Boggs (US) LLP<br>
			2550 M Street, NW<br>
			Washington, D.C.&nbsp; 20037<br>
			<br>
			O&nbsp;&nbsp;&nbsp; +1 202 457 6000<br>
			F&nbsp;&nbsp;&nbsp; +1 202 457 6315<br>
			squirepattonboggs.com</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 31, 2023</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Board of Directors<br>
NovaBay Pharmaceuticals, Inc.<br>
2000 Powell Street, Suite 1150<br>
Emeryville, CA 94608</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Re:</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Registration on Form S-8</b></p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Ladies and Gentlemen:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We have acted as counsel to NovaBay Pharmaceuticals, Inc., a Delaware corporation (the &#8220;Company&#8221;), in connection with a Registration Statement on Form S-8 (together with all exhibits thereto, the &#8220;Registration Statement&#8221;) filed by the Company with the United States Securities and Exchange Commission (the &#8220;Commission&#8221;) on the date hereof relating to the registration under the Securities Act of 1933, as amended (the &#8220;Act&#8221;), of 81,417 additional shares of the Company&#8217;s common stock, par value $0.01 per share (the &#8220;Plan Shares&#8221;), reserved for issuance pursuant to the evergreen provision for fiscal year 2023 of the Company&#8217;s 2017 Omnibus Incentive Plan (the &#8220;Plan&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In connection with our representation of the Company, and as a basis for the opinion hereinafter set forth, we have examined the Registration Statement and such documents, corporate records and other instruments as we have deemed necessary or appropriate for purposes of this opinion. In such examination and in rendering our opinion, we have assumed and have relied upon (i) the authenticity of all documents, certificates, records and instruments submitted to us as originals, the genuineness of all signatures, (ii) the legal capacity of all natural persons, (iii) the truth, accuracy and completeness of the information, representations and warranties contained in the Registration Statement and other records, documents, instruments and certificates we have reviewed, and (iv) the conformity to authentic originals of all documents, certificates, records and instruments submitted to us as copies. Insofar as this opinion relates to Plan Shares to be issued in the future, we have assumed that all applicable laws, rules and regulations in effect at the time of issuance are the same as such laws, rules and regulations in effect as of the date hereof. We have also assumed that the Plan Shares, when issued, will be duly authenticated by the transfer agent and registrar for the Plan Shares, that there will be no changes in the documents, certificates, records and instruments that we have examined, that all Plan Shares will be issued in the manner stated in the Registration Statement, that the Company&#8217;s Board of Directors, or a duly authorized committee thereof, will take all necessary corporate action, including under the terms of the Plan, to authorize and approve the issuance of Plan Shares and that, at all times prior to the issuance of the Plan Shares, the Company will maintain a sufficient number of authorized but unissued shares of common stock available for issuance.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 50%; vertical-align: top;"><b>Squire Patton Boggs (US) LLP</b></td>
			<td style="width: 50%; padding-left: 99pt;">Board of Directors<br>
			NovaBay Pharmaceuticals, Inc.<br>
			March 31, 2023</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Based upon and subject to the foregoing qualifications, assumptions and limitations and subject to the further qualifications set forth in this opinion letter, we are of the opinion that the Plan Shares, when issued, delivered and paid for in accordance with the terms of the Plan, including any applicable award agreements, will be validly issued, fully paid and non-assessable.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Our opinion is limited to the General Corporation Law of the State of Delaware as in effect on the date hereof (including the applicable provisions of the Delaware Constitution and the reported judicial decisions interpreting the General Corporation Law of the State of Delaware as of the date hereof). We do not express any opinion as to the laws of any other jurisdiction. The opinion expressed above is limited to the matters stated in this opinion letter, and no opinion is implied or may be inferred beyond those expressly stated in this opinion letter.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We hereby consent to the filing of this opinion with the Commission as an exhibit to the Registration Statement and to the use of our name therein. In giving such consent, we do not admit that we are within the category of persons whose consent is required under Section 7 of the Act or under the rules and regulations of the Commission.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">This opinion is furnished to you in connection with the filing of the Registration Statement, and is not to be used, circulated, quoted or otherwise relied upon for any other purpose, except as expressly provided in the preceding paragraph. This opinion is given as of the effective date of the Registration Statement, and we assume no obligation to update or supplement this opinion letter contained herein to reflect any facts or circumstances which may hereafter come to our attention or any changes in laws or judicial decisions which may hereafter occur.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:27%;">&nbsp;</td>
			<td style="vertical-align:top;width:27%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Sincerely,</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Squire Patton Boggs (US) LLP</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Squire Patton Boggs (US) LLP</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>ex_495178.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<html><head>
	<title>ex_495178.htm</title>

	<!-- Generated by ThunderDome Portal - 3/31/2023 7:52:36 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;">
<p style="margin: 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 23.1</b></font></p>

<p style="margin: 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We hereby consent to the incorporation by reference in this Registration Statement on Form S-8, pertaining to the NovaBay Pharmaceuticals, Inc. 2017 Omnibus Incentive Plan, of our report dated March 31, 2023, relating to the consolidated financial statements of NovaBay Pharmaceuticals, Inc. appearing in the entity&#8217;s Annual Report on Form 10-K for the year ended December 31, 2022.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:26.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>/s/ WithumSmith+Brown, PC</i></p>
			</td>
			<td style="vertical-align:top;width:26.7%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:auto;">&nbsp;</td>
			<td style="vertical-align:top;width:auto;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">San Francisco, California</p>
			</td>
			<td style="vertical-align:top;width:auto;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">March 31, 2023</p>
			</td>
			<td style="vertical-align:top;width:auto;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>4
<FILENAME>ex_494385.htm
<DESCRIPTION>EXHIBIT FILING FEES
<TEXT>
<html><head>
	<title>ex_494385.htm</title>

	<!-- Generated by ThunderDome Portal - 3/29/2023 5:38:29 AM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="margin: 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 107</b></font></p>

<p style="margin: 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Calculation of Filing Fee Table</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">S-8</p>

<hr class="hr-custom" style="text-align: center;height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 0pt auto 0pt auto;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Form Type)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">NovaBay Pharmaceuticals, Inc.</p>

<hr class="hr-custom" style="text-align: center;height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 0pt auto 0pt auto;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Exact Name of Registrant as Specified in its Charter)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><u>Table 1: Newly Registered Securities</u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 100%;">

		<tr>
			<td style="border-width: 1px; border-style: solid; border-color: black black rgb(0, 0, 0); vertical-align: bottom; width: 4.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Security</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Type</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 13.1%; border-top: 1px solid black; border-right: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Security</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Class Title<sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 6.5%; border-top: 1px solid black; border-right: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Fee<br>
			Calculation<br>
			or Carry<br>
			Forward<br>
			Rule</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 6.2%; border-top: 1px solid black; border-right: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Amount</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Registered<sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 6%; border-top: 1px solid black; border-right: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Proposed<br>
			Maximum<br>
			Offering<br>
			Price Per<br>
			Share</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 6.2%; border-top: 1px solid black; border-right: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Maximum<br>
			Aggregate<br>
			Offering<br>
			Price<sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 5.8%; border-top: 1px solid black; border-right: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Fee Rate</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 6.4%; border-top: 1px solid black; border-right: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Amount of<br>
			Registration<br>
			Fee</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 4.9%; border-right: 1px solid black; border-left: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Equity</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 13.1%; border-right: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Common Stock, par value $0.01 per share<sup style="vertical-align:top;line-height:120%;font-size:pt">(3)</sup></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 6.5%; border-right: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">457(c), (h)</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 6.2%; border-right: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">81,417</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 6%; border-right: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">$1.615</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 6.2%; border-right: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">$131,489</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 5.8%; border-right: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">0.00011020</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 6.4%; border-right: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">$14.50</p>
			</td>
		</tr>
		<tr>
			<td colspan="4" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 30.7%; border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Total Offering Amounts:</b></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 6%; border-right: 1px solid black;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 6.2%; border-right: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">$131,489</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 5.8%; border-right: 1px solid black;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 6.4%; border-right: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">$14.50</p>
			</td>
		</tr>
		<tr>
			<td colspan="4" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 30.7%; border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Total Fees Previously Paid:</b></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 6%; border-right: 1px solid black;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 6.2%; border-right: 1px solid black;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 5.8%; border-right: 1px solid black;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 6.4%; border-right: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8212;</p>
			</td>
		</tr>
		<tr>
			<td colspan="4" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 30.7%; border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Total Fee Offsets:</b></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 6%; border-right: 1px solid black;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 6.2%; border-right: 1px solid black;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 5.8%; border-right: 1px solid black;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 6.4%; border-right: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#8212;</p>
			</td>
		</tr>
		<tr>
			<td colspan="4" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 30.7%; border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Net Fee Due:</b></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 6%; border-right: 1px solid black;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 6.2%; border-right: 1px solid black;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 5.8%; border-right: 1px solid black;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 6.4%; border-right: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">$14.50</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">(1)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">This represents an automatic increase in the number of shares of common stock of the registrant reserved for issuance under the NovaBay Pharmaceuticals, Inc. 2017 Omnibus Incentive Plan, pursuant to an evergreen provision contained in Section 4(a) therein. Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), this Registration Statement also covers any additional securities that may from time to time be offered or issued resulting from any stock splits, stock dividends, recapitalizations or other similar transactions.</p>
			</td>
		</tr>
		<tr>
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: auto;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">(2)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">This calculation is made solely for the purpose of determining the registration fee pursuant to the provisions of Rule 457(c) and (h) under the Securities Act, based on the average of the high and low sales prices of the registrant&#8217;s common stock on March 27, 2023, as reported by NYSE American LLC.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>spblogo.jpg
<TEXT>
begin 644 spblogo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 L17AI9@  34T *@    @  0$Q  (
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>HH V+:VAL[:.WM8DAAB4)'&BX50.@ ["BBB@#__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
